AstraZeneca shares closed at 7,103.65 on February 13, 2025 (NSE) and has given 8.13% returns over the last 6 months and 32.58% over last 12 months. Reported Standalone quarterly numbers for AstraZeneca Pharma are: Net Sales at Rs 440.29 crore in December 2024 up 43.98% from Rs. 305.79 crore in 2023. Net Profit at Rs. 30.85 crore in January 2024 up 95.24% from £15.80 crore in Dec 2023 and EBITDA at £84.97 crore in Jan 2024 up 243.87%. EPS has increased to Rs. 12.34 in January 2025 from £6.32 in December 2023, and Diluted EPS has risen to £12.37 from £ 6.32. Shareholding: Pledged/Encumbered – Number of shares (Crores) — — — – Per. of Shares (as a % of the total sh. of Promoters and Promoter Group Shareholding) —- — –. Non-encumbered – number of shares. (Crore) — — — — per. share (as % of total Share Cap. of the company) –— — — Source : Dion Global Solutions Limited.
